EHA 2022 | Real-world outcomes of patients with MF treated with fedratinib post-ruxolitinib discontinuation
Francesco Passamonti
• 11 Jun 2022
Francesco Passamonti, MD, University of Insubria, Varese, Italy, shares the results of a real-world studying investigating the efficacy of fedratinib in patients with primary myelofibrosis who have been treated with fedratinib after ruxolitinib discontinuation. The study demonstrated a survival advantage for patients who were treated with fedratinib versus those who weren’t after ruxolitinib discontinuation. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
